Humacyte Inc (NASDAQ:HUMA)’s traded shares stood at 3.55 million during the last session, with the company’s beta value hitting 1.37. At the close of trading, the stock’s price was $4.51, to imply a decrease of -3.01% or -$0.14 in intraday trading. The HUMA share’s 52-week high remains $9.97, putting it -121.06% down since that peak but still an impressive 45.01% since price per share fell to its 52-week low of $2.48. The company has a valuation of $562.82M, with an average of 11.17 million shares in intraday trading volume over the past 10 days and average of 4.41 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Humacyte Inc (HUMA), translating to a mean rating of 1.29. Of 2 analyst(s) looking at the stock, 0 analyst(s) give HUMA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.26.
Humacyte Inc (NASDAQ:HUMA) trade information
After registering a -3.01% downside in the last session, Humacyte Inc (HUMA) has traded red over the past five days. The 5-day price performance for the stock is 19.10%, and 0.67% over 30 days. With these gigs, the year-to-date price performance is 59.15%. Short interest in Humacyte Inc (NASDAQ:HUMA) saw shorts transact 20.33 million shares and set a 6.37 days time to cover.
The extremes give us $6 and $10 for target low and target high price respectively. As such, HUMA has been trading -121.73% off suggested target high and -33.04% from its likely low.
Humacyte Inc (HUMA) estimates and forecasts
Looking at statistics comparing Humacyte Inc share performance against respective industry, we note that the company has underperformed competitors. Humacyte Inc (HUMA) shares are -9.60% down over the last 6 months, with its year-to-date growth rate lower than industry average at -18.69% against 16.70%.
Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 1.78M.
HUMA Dividends
Humacyte Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Humacyte Inc insiders hold 26.87% of total outstanding shares, with institutional holders owning 30.01% of the shares at 41.04% float percentage. In total, 30.01% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 7.14 million shares (or 6.5961% of shares), all amounting to roughly $34.27 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 4.73 million shares, or about 4.3693% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.7 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Humacyte Inc (HUMA) shares. Going by data provided on Sep 30, 2024 , SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 2.84 shares. This is just over 2.26% of the total shares, with a market valuation of $12.8 million. Data from the same date shows that the other fund manager holds a little less at 2.59, or 2.06% of the shares, all valued at about 11.69 million.
